BIO-TECHNE Corp (NASDAQ:TECH) announced a quarterly dividend on Wednesday, February 7th, Wall Street Journal reports. Shareholders of record on Friday, February 16th will be paid a dividend of 0.32 per share by the biotechnology company on Friday, March 2nd. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.91%. The ex-dividend date is Thursday, February 15th.
BIO-TECHNE (TECH) traded up $4.06 during midday trading on Thursday, hitting $141.06. The company had a trading volume of 187,500 shares, compared to its average volume of 183,536. BIO-TECHNE has a fifty-two week low of $98.22 and a fifty-two week high of $143.64. The company has a quick ratio of 2.49, a current ratio of 3.10 and a debt-to-equity ratio of 0.36. The firm has a market cap of $5,133.94, a PE ratio of 46.25, a PEG ratio of 2.51 and a beta of 0.78.
BIO-TECHNE (NASDAQ:TECH) last issued its quarterly earnings results on Tuesday, February 6th. The biotechnology company reported $1.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.10. BIO-TECHNE had a return on equity of 14.39% and a net margin of 19.17%. The firm had revenue of $154.15 million for the quarter, compared to analyst estimates of $145.93 million. During the same period in the previous year, the company posted $0.81 earnings per share. The company’s quarterly revenue was up 16.9% compared to the same quarter last year. sell-side analysts predict that BIO-TECHNE will post 3.99 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “BIO-TECHNE Corp Announces Quarterly Dividend of $0.32 (TECH)” was originally published by Week Herald and is the sole property of of Week Herald. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://weekherald.com/2018/02/15/bio-techne-corp-declares-quarterly-dividend-of-0-32-tech.html.
BIO-TECHNE Company Profile
Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world.
Receive News & Ratings for BIO-TECHNE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIO-TECHNE and related companies with MarketBeat.com's FREE daily email newsletter.